What is the CTNM 30-day expected price range?

As of May 29, 2026, with CTNM at $13.41 and ATM IV at 158.3%, the implied 30-day one-standard-deviation range is approximately ±$6.09, or about $7.32 to $19.50. IV rank is subdued, so the priced distribution is tighter than the 1-year typical width.

What does CTNM risk-neutral density tell us?

Risk-neutral density is the probability distribution of future CTNM price implied by listed option prices. Extracted via Breeden-Litzenberger (twice-differentiating the call price function with respect to strike), it represents the pricing kernel rather than the real-world probability of outcomes. Persistent skew or fat-tail features in the density reflect how the market is pricing tail risk.

How does CTNM ATM IV translate to a probability range?

ATM IV is annualized; multiplying by sqrt(t/365) scales it to the chosen tenor. Under lognormal assumptions, the resulting standard deviation defines the ±1σ band that contains roughly 68% of outcomes, ±2σ for 95%. Empirical equity returns have fatter tails than log-normal, so the implied tail probabilities under-state realized tail frequency in stressed regimes.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Probability Analysis

Probability analysis extracts the risk-neutral probability distribution implied by option prices. It shows the market-implied likelihood of the underlying reaching various price levels by expiration.

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $502.5M, listed on NASDAQ, employing roughly 41 people, carrying a beta of 0.89 to the broader market. Contineum Therapeutics, Inc. Led by Carmine N. Stengone, public since 2024-04-05.

Snapshot as of May 29, 2026.

Spot Price: $13.41
ATM IV: 158.3%
IV Rank: 27.7%
IV Percentile: 22.8%
HV 20-Day: 54.8%
IV Skew 25Δ: -0.969

As of May 29, 2026, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) at $13.41 has an ATM IV of 158.3%, implying a 30-day one-standard-deviation range of approximately ±$6.09. IV rank is 27.7% (subdued, distribution priced tighter than usual). IV percentile is 22.8%. The 25-delta skew is -0.969: downside tail priced richer than upside, biasing probability mass below spot. Under lognormal assumptions roughly 68% of outcomes fall within ±1σ and 95% within ±2σ; risk-neutral probability analysis refines this by extracting the market-implied distribution directly from options prices, capturing the fat tails that real markets exhibit.

How CTNM probability analysis Data Feeds Strategy Selection

Strategy selection on Contineum Therapeutics, Inc. Class A Common Stock options does not derive from any single metric in isolation. The probability analysis view above sits inside a broader read: ATM IV currently sits at 158.3% and dealer gamma exposure is positive, so dealer hedging is mechanically mean-reverting. Combine the probability analysis data here with the volatility-skew surface, dealer-gamma exposure, max-pain level, and upcoming-events calendar to build a positioning thesis. Risk-defined structures (credit spreads, debit spreads, iron condors) are usually safer than naked positions while the regime is uncertain; the data on this page anchors the inputs but does not by itself constitute a trade thesis.

How to read the CTNM probability distribution

The probability cone above is the option-market-implied distribution of where Contineum Therapeutics, Inc. Class A Common Stock spot could end up at expiration. It's derived from the implied-volatility surface via a risk-neutral pricing transformation, not from historical realized returns. With ATM IV at 158.3% and spot at $13.41, the 1σ band is approximately ±54.6% over a 30-day horizon. Recent realized HV-20 of 54.8% runs 103.5 vol points below the current implied, suggesting the chain is pricing more dispersion than the underlying has been delivering.

CTNM risk-neutral vs real-world probabilities

The probabilities derived from option prices reflect the market's risk-adjusted view, not the realized statistical distribution. Risk-neutral probabilities include the equity risk premium and skew preferences priced into options, so they tend to overstate tail probability and understate upside drift relative to actually-realized outcomes. CTNM's put-skewed 25-delta surface (-0.969) means downside risk-neutral probabilities are higher than upside - the empirical bias is well-documented. For probability-of-touch calculations and assignment-risk modeling, risk-neutral is the right benchmark. For position-sizing your own conviction, blend with realized-volatility-based statistics from the HV columns.

Trading the CTNM distribution

Probability-driven strategies aim to capture mispricings between the implied distribution and your own probability assessment. Premium-selling structures (credit spreads, iron condors, cash-secured puts) profit when the implied distribution overprices tail probability relative to realized; premium-buying (debit spreads, long calls/puts, long straddles) profits in the reverse. With CTNM IV rank at 27.7%, the chain is pricing tighter tails than recent realized history; buyers get cheaper optionality but need a real catalyst to monetize. Always pair probability-driven strategy selection with a stop loss or wing-defined risk - the implied distribution is a snapshot, and regime shifts can invalidate it intraday.

Learn how risk-neutral density is reported and how to read the data →

Frequently asked CTNM probability analysis questions

What is the CTNM 30-day expected price range?: As of May 29, 2026, with CTNM at $13.41 and ATM IV at 158.3%, the implied 30-day one-standard-deviation range is approximately ±$6.09, or about $7.32 to $19.50. IV rank is subdued, so the priced distribution is tighter than the 1-year typical width.
What does CTNM risk-neutral density tell us?: Risk-neutral density is the probability distribution of future CTNM price implied by listed option prices. Extracted via Breeden-Litzenberger (twice-differentiating the call price function with respect to strike), it represents the pricing kernel rather than the real-world probability of outcomes. Persistent skew or fat-tail features in the density reflect how the market is pricing tail risk.
How does CTNM ATM IV translate to a probability range?: ATM IV is annualized; multiplying by sqrt(t/365) scales it to the chosen tenor. Under lognormal assumptions, the resulting standard deviation defines the ±1σ band that contains roughly 68% of outcomes, ±2σ for 95%. Empirical equity returns have fatter tails than log-normal, so the implied tail probabilities under-state realized tail frequency in stressed regimes.